Pentagon eyeing Chinese production of tainted 'sartan' API as trade war grows

The Pentagon is scrutinizing Chinese-made API in "sartan" drugs as a possible health threat. (Getty)

A series of FDA recalls on “sartan” active ingredients made abroad has shaken the drug industry’s confidence in the manufacturing process used for the generic blood pressure medications. Now, with trade pressure ramping up, the Pentagon is eyeing China’s API production as a potential health crisis.

The Defense Health Agency (DHA) is scrutinizing increased Chinese production of the API behind a range of popular “sartan” drugs, including losartan and valsartan, as a health threat for military members who use the drugs. The worldwide recalls stemmed from API made by a Chinese supplier.

"The national security risks of increased Chinese dominance of the global API market cannot be overstated," Christopher Priest, acting deputy assistant director for healthcare operations and Tricare for the DHA, told a U.S.-China advisory panel last week in Washington.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The Pentagon’s heightened focus on Chinese API production comes as the two countries engage in an increasingly acrimonious “trade war” that has become a hallmark moment in President Donald Trump’s term in office. With a new round of tariffs on Chinese goods likely, the National Security Council is looking into Chinese drug manufacturing and trying to identify the most at-risk medications, according to Stars & Stripes.

RELATED: FDA declares 40 generics free of carcinogens as 'sartan' recalls continue

The FDA launched a global recall in 2018 after a U.S. drug manufacturer found high levels of N-nitrosodimethylamine (NDMA) in the valsartan active ingredient it had bought from a Chinese supplier. Since then, the FDA discovered that NDMA, N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) and NDEA—all considered unsafe at certain levels—can be created during sartan drug manufacturing under certain conditions. 

In early April, the FDA cleared 40 angiotensin II receptor blockers that are free of those three potentially carcinogenic compounds as a worldwide shortage in losartan continues to pinch the global market.

RELATED: FDA temporarily retreats from impurity standards as losartan shortages loom

That losartan shortage led the FDA to back off its own impurity standards for losartan active ingredients in late March, freeing drugmakers to sell products with impurities above the prescribed level for six months.

The FDA argued that scientists believe the risks associated with the impurities are low to begin with and six months of patient exposure likely wouldn’t pose any new health concerns. The relaxed rules only applied to losartan and the impurity NMBA.

Suggested Articles

That didn’t take long. Sanofi CEO Paul Hudson has only been at the reins for a couple months, but on Tuesday, he unveiled a major shakeup.  

New "gold standard" data could further increase doctors' confidence in multiple myeloma med Darzalex, Johnson & Johnson says.

Could Monday's cancer buyout be a hint about what Sanofi CEO Paul Hudson will unveil at Tuesday's investor confab? Analysts think so.